A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype

被引:19
|
作者
Kerem, E
NissimRafinia, M
Argaman, Z
Augarten, A
Bentur, L
Klar, A
Yahav, Y
Szeinberg, A
Hiba, O
Branski, D
Corey, M
Kerem, B
机构
[1] HEBREW UNIV JERUSALEM, DEPT GENET, IL-91904 JERUSALEM, ISRAEL
[2] CHAIM SHEBA MED CTR, DEPT PAEDIAT, CF CLIN, IL-52621 TEL HASHOMER, ISRAEL
[3] RAMBAM MED CTR, DEPT PAEDIAT, CF CLIN, HAIFA, ISRAEL
[4] BIKUR CHOLIM HOSP, DEPT PAEDIAT, JERUSALEM, ISRAEL
[5] HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA
关键词
cystic fibrosis; genotype-phenotype correlation; genetics; pancreatic function; pulmonary function; CFTR mutation;
D O I
10.1542/peds.100.3.e5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. Cystic fibrosis (CF) has variable clinical presentation. Disease severity is partially associated with the type of mutation. The aim of this study was to report genotype-phenotype analysis of the G85E mutation. Patients. The phenotype of 12 patients (8 were from the same extended family, and 5 of them were siblings from 2 families) carrying at least one copy of the G85E mutation was evaluated and compared with the phenotype of 40 patients carrying the two severe mutations, W1282X and/or Delta F508 (group 1), and with 20 patients carrying the splicing mutation, 3849+10kb C->T, which was found to be associated with milder disease (group 2). Results. A high phenotypic variability was found among the patients carrying the G85E mutation. This high variability was found among patients carrying the same genotype and among siblings. All the studied chromosomes carrying the G85E mutation had the 7T variant in the polythymidine tract at the branch/acceptor site in intron 8. Of the G85E patients, 25% had pancreatic sufficiency and none had meconium ileus, compared with 0% and 32%, respectively, of patients from group 1, and 80% and 0%, respectively, from group 2. Two patients carrying the G85E mutation had sweat chloride levels <60 mmol/L whereas all the others had typically elevated levels >80 mmol/L. Compared with group 2, patients carrying the G85E mutation were diagnosed at an earlier age and had higher sweat chloride levels, with mean values similar to group 1 but significantly more variable. Forced expiratory volume in 1 second (FEV1) was similar in the three groups, with no differences in the slope or in age-adjusted mean values of FEY. The levels of transcripts lacking exon 9 transcribed from the G85E allele measured in 3 patients were 55%, 49%, and 35% and their FEV1 values were 82%, 83%, and 50% predicated, respectively. Conclusions. The G85E mutation shows variable clinical presentation in all clinical parameters. This variability could be seen among patients carrying on the other chromosome the same CFTR mutation, and also among siblings. This variability is not associated with the level of exon 9 skipping. Thus, the G85E mutation cannot be classified either as a severe or as a mild mutation.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Cystic Fibrosis Transmembrane Conductance Regulator Mutation Spectrum in Patients with Cystic Fibrosis in Tunisia
    Fredj, Sondess Hadj
    Messaoud, Taieb
    Templin, Carine
    des Georges, Marie
    Fattoum, Slaheddine
    Claustres, Mireille
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2009, 13 (05) : 577 - 581
  • [2] Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype
    Sosnay, Patrick R.
    Raraigh, Karen S.
    Gibson, Ronald L.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2016, 63 (04) : 585 - +
  • [3] The cystic fibrosis transmembrane conductance regulator and ATP
    Devidas, S
    Guggino, WB
    CURRENT OPINION IN CELL BIOLOGY, 1997, 9 (04) : 547 - 552
  • [4] Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
    Barbry, Pascal
    Marcet, Brice
    Caballero, Ignacio
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (10) : 1214 - 1216
  • [5] Biosynthesis of cystic fibrosis transmembrane conductance regulator
    Pranke, Iwona M.
    Sermet-Gaudelus, Isabelle
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 52 : 26 - 38
  • [6] THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    RIORDAN, JR
    ANNUAL REVIEW OF PHYSIOLOGY, 1993, 55 : 609 - 630
  • [7] Glycosylation and the cystic fibrosis transmembrane conductance regulator
    Scanlin, TF
    Glick, MC
    RESPIRATORY RESEARCH, 2001, 2 (05) : 276 - 279
  • [8] Cystic Fibrosis Transmembrane Conductance Regulator and Pseudomonas
    Zemanick, Edith T.
    Accurso, Frank J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (07) : 763 - 765
  • [9] Glycosylation and the cystic fibrosis transmembrane conductance regulator
    Thomas F Scanlin
    Mary Catherine Glick
    Respiratory Research, 2
  • [10] Novel missense mutation in exon 16 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene identified in CBAVD patients
    Bienvenu, T
    Hubert, D
    Setbon, E
    Dusser, D
    Kaplan, JC
    Beldjord, C
    HUMAN MUTATION, 1996, 7 (02) : 182 - 182